Agoracom Blog Home

Posts Tagged ‘Hexo Corp’

Avicanna $AVCN.ca $AVCNF Enters Multi-level Strategic Partnership with Al Harrington’s, Harrington Wellness Inc., to Commercialize re+PLAY™ Branded Products in Canada $WEED.ca $CL.ca $HEXO.ca

Posted by AGORACOM-JC at 8:46 AM on Tuesday, February 9th, 2021
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • Development and licensing of a bespoke and evidence-based athletic line of CBD topical products for the re+PLAY brand in the U.S.
  • Avicanna to lead commercialization in Canada through consumer retail and medical sales channels.

TORONTO, Feb. 09, 2021 — Avicanna Inc. (“ Avicanna ” or the “ Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that the Company has entered into an intellectual property licensing and royalty agreement with Harrington Wellness Inc. (“ Harrington Wellness” ) for the commercialization of a CBD topical product line targeting athletes and active consumers in Canada and the U.S. (the “ re+PLAY Agreement ”). 

Avicanna and Harrington Wellness have worked together extensively on researching, developing and optimizing a bespoke line of CBD-based topicals designed specifically for the athletic and sports community (the “ re+PLAY Products” ). These CBD-based topicals utilize Avicanna’s proprietary deep tissue technology for cannabinoid delivery and have been curated with the support of Harrington Wellness’ deep understanding of the needs of professional athletes. The products are planned to be launched in Q2 2021 in the United States by Harrington Wellness across retail and e-commerce channels and in Canada through medical and adult-use/consumer retail cannabis sales channels by Avicanna. The product formulations are also enrolled in several preclinical studies with leading Canadian medical institutions to assess their efficacy in chronic pain and osteoarthritis. 

Under the re+PLAY Agreement, which has an initial three-year term, Avicanna has licensed the use of certain proprietary product formulations to Harrington Wellness to be used in connection with the manufacture and distribution of the re+PLAY Products in the United States. Additionally, Harrington Wellness has also licensed the use of the re+PLAY brand to Avicanna to be used in connection with the manufacture and distribution of the re+PLAY Products in Canada. The re+PLAY Products will be branded and sold under the re+PLAY brand in both the United States and Canada. Royalties are payable to Avicanna and Harrington Wellness as consideration for each of the licenses. 

“As a former professional athlete myself and avid CBD user, I understand the importance of being in peak physical condition and finding products that help you to recover faster,” says Al Harrington, CEO of Harrington Wellness. “Avicanna has been an incredible partner in developing the re+PLAY formulas and expanding the product line’s availability into Canada.” 

In commenting on the re+PLAY Agreement, Aras Azadian, CEO of Avicanna said, “I am thrilled to finally introduce our relationship with Al Harrington and Harrington Wellness. This partnership was formed on the alignment of the vision to introduce premium and scientifically backed products for athletic and active consumers to the market. Additionally, the distinct expertise of the two companies and collaborative spirit has yielded an advanced and evidence-based line of products that are tailored to promote a healthy active lifestyle for the athlete in all of us.” 

To the knowledge of the Company, it is in compliance with all applicable laws in the jurisdictions in which it operates. 

About Harrington Wellness  

Founded in 2018 by Viola CEO and NBA Vet, Al Harrington, Harrington Wellness produces a wide range of products via in house manufacturing, joint venture projects and white label arrangements with other vetted organizations that stand for the highest quality and reliable medical benefits. These items are sold online via in house and existing marketplace sites, in brick and mortar retail and by health professions directly in their clinics. 

Harrington Wellness’ hero brand, re+PLAY™ is a performance based CBD wellness brand created with the combined knowledge and experience of athletes, doctors, and certified athletic trainers. Our team is dedicated to creating best in class products that deliver the powerful healing properties of the plant to our customers. All products are made using a triple-tested process with hemp grown in the USA, and are free of heavy metals, pesticides, and harmful microbes. 

Read More: https://agoracom.com/ir/Avicanna/forums/discussion/topics/754961-avicanna-enters-multi-level-strategic-partnership-with-al-harrington-s-harrington-wellness-inc-to-commercialize-re-play-branded-products-in-canada/messages/2302800#message

Avicanna $AVCN.ca $AVCNF Launches RHO Phyto™ Topical Gels in Canada and Initiates Clinical Studies $TRUL.ca $ACB

Posted by AGORACOM-JC at 7:59 AM on Thursday, January 28th, 2021
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • RHO Phyto Deep Tissue Gels will be initially available on the Medical Cannabis by Shoppers Drug Mart™ online platform and expanded into specific consumer retail channels in February 2021.
  • Initiation of osteoarthritis preclinical trials in Canada in addition to the enrollment of the products into the UHN MC-RWE study to evaluate the effectiveness on pain, sleep, anxiety, and depression.

TORONTO, Jan. 28, 2021 — Avicanna Inc. (“ Avicanna ” or the “ Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce the launch of the RHO Phyto™ Deep Tissue Gels (the “ RHO Phyto Deep Tissue Gels ”) through Medical Cannabis by Shoppers Drug Mart as well as through additional adult use channels. The Company is also pleased to announce the initiation of pre-clinical osteoarthritis evaluations after successful in vitro studies and the enrollment of the Deep Tissue Gels in the Medical Cannabis Real World Evidence (“ MC-RWE ”) study. The MC-RWE study is led by the University Health Network (“ UHN ”) with the goal to evaluate the effectiveness of medical cannabis on pain, sleep and other related comorbidities.

About the RHO Phyto Deep Tissue Gels

The RHO Phyto Deep Tissue Gels synergistically combine natural clove oil and menthol with cannabinoids and natural polyphenols in advanced emulsions which are optimized for faster absorption and deeper delivery. The RHO Phyto Deep Tissue Gel formulations are also designed for long term cannabinoid shelf-life stability and accurate dosing with cooling sensation, and pleasant mint aroma. The deep tissue technology has been developed and optimized by Avicanna’s research and development team. Over the last 3 years, the RHO Phyto Deep Tissue Gel formulations have been validated by a series of preclinical studies where both stability and enhanced absorption into the deeper layers of the skin were shown.

Read More: https://agoracom.com/ir/Avicanna/forums/discussion/topics/754105-avicanna-launches-rho-phyto-topical-gels-in-canada-and-initiates-clinical-studies/messages/2300727#message

Avicanna $AVCN.ca $AVCNF Initiates Pre-Clinical and Behavioural Studies on its RHO Phyto™ Formulary with University of Guelph and Provides Research and Management Team Updates $WEED.ca $CL.ca $HEXO.ca

Posted by AGORACOM-JC at 8:07 AM on Thursday, January 21st, 2021
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • Updated and amended its collaboration with Dr. Jibran Khokhar, Assistant Professor at the University of Guelph, and initiated prioritized pre-clinical studies on the RHO Phyto formulations that are commercialized in Canada and Colombia.
  • Additionally, the Company provides an update on research projects with the University of Toronto and Thompson Rivers University as well as a change to its management team.

TORONTO, Jan. 21, 2021– Avicanna Inc. (“ Avicanna ” or the “ Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products has updated and amended its collaboration with Dr. Jibran Khokhar, Assistant Professor at the University of Guelph, and initiated prioritized pre-clinical studies on the RHO Phyto formulations that are commercialized in Canada and Colombia. Additionally, the Company provides an update on research projects with the University of Toronto and Thompson Rivers University as well as a change to its management team.

Initiation of pre-clinical studies on RHO Phyto in collaboration with University of Guelph

Further to Avicanna’s previous announcement regarding Dr. Khokhar’s research team at the University of Guelph being awarded a Natural Sciences and Engineering Research Council of Canada (“ NSERC ”) Alliance grant focused on the neurobiological underpinnings of cannabis toxicosis with the aim to evaluate Avicanna’s formulations in the treatment of cannabis-induced toxicosis, the project is now being expanded. The expansion of the project includes pharmacokinetic and behavioural testing of Avicanna’s RHO Phyto™ formulations as well as studying their efficacy in alleviating neuropathic pain and addiction. The data generated from the research will help guide Avicanna’s clinical development, including the pharmaceutical and real-world evidence studies related to the RHO Phyto formulations, and will provide additional information to health care practitioners who are recommending and prescribing the products in several markets.

COVID-19 drug candidate project update

The research collaboration with the University of Toronto on the development of a drug candidate to treat lung inflammation caused by COVID-19, with funding support from an NSERC Alliance grant and a MITACS Alliance grant, is complete. The peer-reviewed grants were focused on the development of a cannabinoid formulation to be used for further research on COVID-19. The physical and chemical characterization of the optimized cannabinoid formulation is complete, which included its stability and drug release properties in relevant conditions.

COVID-19 and anti-inflammatory related research collaboration with TRU with non-dilutive funding

In partnership with Avicanna, Dr. Kingsley Donkor and collaborators from Thompson Rivers University (” TRU ”), will be evaluating naturally derived cannabinoids and candidate formulations for their efficacy to modulate the receiving receptor of COVID-19 (angiotensin-converting ACE2 gene expression). This project will focus on elucidating the mechanism of action of novel prophylactic nasal and oral cannabinoid products for humans that target ACE2 viral gateways. Candidate formulations, once identified, will be evaluated for anti-inflammatory effects in human-derived lung tissue models. The research with TRU is supported by an NSERC grant and a MITACS Internship.

Read More: https://agoracom.com/ir/Avicanna/forums/discussion/topics/753556-avicanna-initiates-pre-clinical-and-behavioural-studies-on-its-rho-phyto-formulary-with-university-of-guelph-and-provides-research-and-management/messages/2299215#message

Avicanna $AVCN.ca $AVCNF to Expand Access to Its Advanced and Evidence-Based RHO Phyto Medical Products Through Provincial Retailers Across Canada $WEED.ca $CL.ca $HEXO.ca

Posted by AGORACOM-JC at 7:52 AM on Wednesday, December 23rd, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • Expanding from the successful launch in medical-only channels in partnership with Medical Cannabis by Shoppers, Avicanna will now offer RHO Phyto™ nationwide through provincial retailers
  • RHO Phyto products will include its advanced formulary of sublingual sprays, oil drops and topicals through retail sales channels estimated at $3 billion dollars* in Canada

TORONTO, Dec. 23, 2020 — Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announces that the full formulary of RHO Phyto products will be available through retail channels in early 2021 in Canada.

A successful proof of concept and partnership with Medical Cannabis by Shoppers

During the past four months, the RHO Phyto medical formulary has experienced an incredibly successful launch with overwhelming positive support by the medical community including 300 prescribers and 20 clinics. RHO Phyto sales have increased 100%+ month over month in all product categories. The early results show the product formulary key demographics are 55% women, 47% are 51-75 years of age and 90% of consumers are 30+ years old. Avicanna will remain exclusive to Medical Cannabis by Shoppers for medical/prescription use and intends to increase its current commercial SKU’s from 4 to 10 in 2021.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/53b6cb70-2cb5-42b1-a891-f43366910e83

Expansion to retail sales to provide consumers with low barrier access to the same industry leading formulary of medical cannabis products

It has become evident that many consumers who seek cannabis for medical purposes are not going through medical channels, with nearly 44% purchasing from legal storefronts (adult-use). According to the 2020 Canadian Cannabis Survey, 76% of medical cannabis users do not have a medical document – such as a prescription – from a healthcare professional. The ease of access to store-fronts and systemic barriers to connecting with a health care professional who may provide a medical document have continued to impact medical user numbers year over year, which have remained largely the same around 350,000 active registered medical users in Canada since 2018*.

Aras Azadian, Avicanna’s Chief Executive Officer, stated: “The existing stigma around medical cannabis and the barriers to obtain a medical document make it particularly challenging for some patients to access medical cannabis through the appropriate channels with the support of a health care practitioner. We believe that by expanding the RHO Phyto portfolio into retail sales channels we will provide consumers with easier and low barrier access to standardized medical products they seek. For a biopharmaceutical company like Avicanna, this expansion of our medical products into retail channels is in many ways similar to accessing over-the-counter medical products.” Aras Azadian, the companies Chief Executive Officer.

RHO Phyto product attributes and retail sales strategy

The advanced and standardized products are offered in various doses of CBD, THC and THC-Free formulations to provide consumers with a range of inhalation-free cannabinoids-based solutions. The advanced formulations are developed and optimized by Avicanna to provide enhanced absorption versus basic MCT (medium-chain triglyceride) oil formulations while providing a consistent experience with a pleasant taste and smell. The RHO Phyto products are delivered with accurate dosing which also allows for easy titration and dosing by consumers.

Avicanna’s RHO Phyto strategy to leverage retail sales channels is consistent with the company’s vision to provide education and safe delivery of its products through evidenced-based training and education to the consumers, retailers and the medical community. Avicanna aims to establish RHO Phyto as the doctor recommended brand within the cannabis industry and has initiated several pre-clinical and real-world evidence clinical trials on the products with leading Canadian medical institutions.

*source: Statistics Canada

About Avicanna Inc.

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.

Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:

  • Pura Earth™ or Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
  • RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all 2 developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.

With ongoing clinical trials on its derma-cosmetic (branded as Pura Earth or Pura H&W), medical cannabis (branded as RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.

Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia.

SOURCE Avicanna Inc.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email at [email protected]

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the ability of the Company to manufacture any of the products, and the ability of the Company to sell any of the products in retail channels in Canada. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 15, 2020 and final short form prospectus dated November 27, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com .

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

CLIENT FEATURE: Avicanna $AVCN.ca $AVCNF A Revenue Generating, Canadian Vertically – Integrated Biopharmaceutical Company $WEED.ca $TLRY $HARV.ca

Posted by AGORACOM-JC at 3:12 PM on Friday, December 11th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

Avicanna (AVCN: TSX) (AVCN: OTCQX) (0NN: FSE) is a vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global marketplace.

Third Quarter Highlights

  • $882K in revenue, an increase of 24% from Q2-2020,
  • Double-digit growth, quarter over quarter from Q4-2019
  • In addition, the Company was able to reach a major milestone with the launch of certain products from its RHO Phyto product line in Canada and further diversified its revenue streams.

When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products as follows:

1.  The company has a full line of high end CBD based skin care products serving the consumer retail segment with Canadian distribution through Medical Cannabis by Shoppers, as well as global distribution later this year. 

2.  Avicanna’s superior medical cannabis line also features products distributed through Medical Cannabis by Shoppers, the online arm of Canada’s largest drugstore chain.

Recently Launched Medical Cannabis Program with its RHO Phyto™ Formulary Nationwide in Colombia (Read More)

Leveraging the successful launch of the Company’s RHO Phyto branded advanced medical cannabis product line in Canada, the portfolio of preparations, including oil drops, sublingual sprays, capsules and topicals, are now available nationwide in Colombia through physician prescription.

  • The medical program includes Avicanna’s 3 pillars aimed at setting the gold standard for medical cannabis in Colombia and other Latin American markets, including
    • Medical community education,
    • Advanced pharmaceutical grade cannabinoid preparations,
    • Comprehensive patient support program

3.  Avicanna also hosts a full pipeline of Pharmaceuticals in various stages of trials to address Dermatology, Psychiatry, Neurology, Pain and Oncology. Three of the company’s products are already as far as phase 2.

AND… if that is not enough …

4.  Avicanna’s Colombian cultivation division hosts 500,000 Sq ft of low cost and USDA certified organic Cannabis Cultivation. The company recently Made History As The First Ever Export Of Feminized Hemp Seeds From Colombia To The United States. 7,000,000 Seeds For $380,000, with an additional 75,000,000 Seeds Available For Export In Several Pending Transactions.

Hub On AGORACOM / Corporate Profile

Avicanna $AVCN.ca $AVCNF Announces Closing of Public Offering of Units $WEED.ca $CL.ca $HEXO.ca

Posted by AGORACOM-JC at 9:32 AM on Tuesday, December 8th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • Announced marketed public offering of 5,966,900 units of the Company at a price of $0.85 per Unit, for gross proceeds of $5,071,865
  • Each Unit is comprised of one common share of the Company and one-half of one common share purchase warrant of the Company
  • Each Warrant is exercisable for one Common Share at a price of $1.20 per share at any time for a period of 36 months following closing of the Offering

TORONTO, ON , Dec. 8, 2020 – Avicanna Inc. (” Avicanna “, or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce the closing of its previously announced marketed public offering of 5,966,900 units (the ” Units “) of the Company at a price of $0.85 per Unit, for gross proceeds of $5,071,865 (the ” Offering “). Each Unit is comprised of one common share of the Company (each a ” Common Share “) and one-half of one common share purchase warrant of the Company (each full warrant, a ” Warrant ” and collectively the ” Warrants “). Each Warrant is exercisable for one Common Share at a price of $1.20 per share at any time for a period of 36 months following closing of the Offering.

The Offering was conducted on a “best efforts” basis by a syndicate of agents led by Echelon Wealth Partners Inc., as lead agent and sole-bookrunner, and including Beacon Securities Limited and Canaccord Genuity Corp. (collectively, the ” Agents “).

Aras Azadian , CEO of Avicanna, commented: “The completion of our first prospectus offering and substantial capital raise since our IPO is a confirmation of the on-going support from our existing and new shareholders during a difficult time in the market. This also coincides with further cost reductions and with the launch of our medical products and several other commercial initiatives across several markets where we intend to use the use the proceeds of this raise to pave the way to sustainability and profitability.”

The Company has granted the Agents an option, exercisable in whole or in part, at the sole discretion of the Agents, at any time for a period of 30 days from and including the closing of the Offering, to purchase from the Company up to an additional 15% of the Units sold under the Offering, on the same terms and conditions of the Offering to cover over-allotments, if any, and for market stabilization purposes (the ” Over-Allotment Option “). The Over-Allotment Option may be exercised by the Agents to purchase additional Units, Common Shares, Warrants or any combination thereof.

The Company intends to use the net proceeds of the Offering for product development, working capital and general corporate purposes.

The securities described in this press release have not been and will not be registered under the United States Securities Act of 1933 , as amended (” U.S. Securities Act “) or any state securities laws. Accordingly, the securities may not be offered or sold in the United States (as such term is defined in Regulation S under the U.S. Securities Act) or to, or for the account or benefit of, a U.S.  person (as such term is defined in Regulation S under the U.S. Securities Act) except pursuant to transactions exempt from registration under the U.S. Securities Act and under the securities laws of any applicable state. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States .

About Avicanna Inc.

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.

Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:

  • Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
  • RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all 2 developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.

With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.

Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta , Colombia . Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020 , Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia .

Stay Connected

For more information about Avicanna, visit www.avicanna.com , call 1-647-243-5283, or contact Setu Purohit , President by email at [email protected] .

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by the Company, including satisfaction of regulatory requirements in various jurisdictions, exercise of the Over-Allotment Option and the use of proceeds from the Offering.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of manageme nt’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, the delay or failure to receive regulatory approvals, and the risk factors set out in the Company’s annual information form dated April 15, 2020 , filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com .

SOURCE Avicanna Inc.

#CBD Oil and Skin Care: What You Need To Know – SPONSOR: Avicanna $AVCN.ca $AVCNF $WEED.ca $CL.ca $HEXO.ca

Posted by AGORACOM-JC at 4:13 PM on Wednesday, December 2nd, 2020

SPONSOR: Avicanna (TSX: AVCN) (OTCQX: AVCNF) (FSE: ONN) is a Canadian vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global market place. When we say vertically integrated, we mean it.  Avicanna has 4 fully operating divisions to address the entire market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Avicanna offers you exposure to the entire vertical. Learn More.

http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

CBD Oil and Skin Care: What You Need To Know

  • Research shows that CBD oil has anti-inflammatory properties that are beneficial to skin health.
  • As such, CBD can be an active ingredient in skincare products that help treat or manage acne and other related breakouts. It is an ideal option for people with reactive skin.
  • Since CBD oil is plant-derived produce, thus, it having antioxidative abilities should not be surprising.
  • The antioxidants can help reduce the signs and impacts associated with aging.
  • The properties counteract free-radicals therein, reducing any inflammation while diminishing noticeable signs like reddish skin tone, wrinkles, and dullness.

By: Natalie Gray November 30, 2020

CBD oil is one of the active ingredients in skincare products that help to manage everything from wrinkles to acne. But is this hemp or marijuana extract as effective as touted? Does it offer any benefits, or is it marketing hype? Below are the facts about CBD gummies and CBD skincare that you need to know.

What Is CBD Oil?

CBD (cannabidiol) is a non-intoxicating compound found in hemp and marijuana plants, extracted in powder form. It is then processed with oil like coconut or olive to enhance its effectiveness as a skincare oil product.

CBD oil made for skincare will not evoke the “high” associate with its counterpart compound THC (tetrahydrocannabinol). While both CBD and THC can be found in hemp and marijuana plants, the hemp plant has a higher CBD and lower THC content than marijuana. At times the THC is so low that it not detectable during testing.

You should not mistake hemp-based CBD oil for hemp seed oil, another effective ingredient found in skincare products. At times, the two are marketed interchangeably, but the CBD oil has a high cannabidiol concentration while hemp seed oil has trace amounts or none.

The FDA regulated the name “CBD” used on products that claim to contain cannabidiol to state the same on the label. The regulated labeling is known as INCI (International Nomenclature of Cosmetic Ingredients). Therefore, products with names, such as CBD-enriched hemp seed oil, might not contain cannabidiol. You can be confident of what you buy is as specified on its label.

CBD For Acne-Prone Skin

According to research, acne is an inflammatory skin condition that could be triggered by various factors. Hence, some people can develop this inflammatory condition because of something they apply or even consume. Studies show that anything that can reduce the swelling and soothe the skin can help manage or treat acne. That is where CBD becomes an alternative solution that can fight the breakouts.

Research shows that CBD oil has anti-inflammatory properties that are beneficial to skin health. As such, CBD can be an active ingredient in skincare products that help treat or manage acne and other related breakouts. It is an ideal option for people with reactive skin.

CBD has been found to potentially lower sebum production, which is a unique quality that can help balance the sebum flow in the skin. But with this encouraging news, scientists still say that more studies are needs for conclusive findings that confirm the full extent of CBD’s benefits in skincare and overall health and wellness.

CBD Oil For Wrinkles And Anti-Aging

Since CBD oil is plant-derived produce, thus, it having antioxidative abilities should not be surprising. The antioxidants can help reduce the signs and impacts associated with aging. The properties counteract free-radicals therein, reducing any inflammation while diminishing noticeable signs like reddish skin tone, wrinkles, and dullness.

With other antioxidant-rich products in the market, it is unwise to claim that CBD is the best option out there. It is one of the many options worth considering if you are keen on finding a safe and better solution to caring for your skin.

CBD Oil For Sensitive Skin

CBD oil is claimed to have soothing compounds since it has been found to have skin-normalizing and skin-calming effects. Such properties are essential in treating and managing skin sensitivity and other related issues like inflammation, reactivity, and redness. With the skin exposed to the elements, different skin types are affected differently by environmental stressors. By applying CBD oil, its soothing mechanism will help keep the skin in check.

Source: http://theleafonline.com/c/lifestyle/2020/11/cbd-oil-and-skin-care-what-you-need-to-know/

CLIENT FEATURE: Avicanna $AVCN.ca $AVCNF A Revenue Generating, Canadian Vertically – Integrated Biopharmaceutical Company $WEED.ca $TLRY $HARV.ca

Posted by AGORACOM-JC at 12:39 PM on Wednesday, November 18th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

Avicanna (AVCN: TSX) (AVCN: OTCQX) (0NN: FSE) is a vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global marketplace.

Third Quarter Highlights

  • $882K in revenue, an increase of 24% from Q2-2020,
  • Double-digit growth quarter over quarter from Q4-2019
  • Reached a major milestone with the launch of certain products from its RHO Phyto product line in Canada and further diversified its revenue streams.

When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products as follows:

1.  The company has a full line of high end CBD based skin care products serving the consumer retail segment with Canadian distribution through Medical Cannabis by Shoppers, as well as global distribution later this year. 

2.  Avicanna’s superior medical cannabis line also features products distributed through Medical Cannabis by Shoppers, the online arm of Canada’s largest drugstore chain. In addition, the company recently received certification and authorization for the sale of pharmaceutical cannabinoid products with medical prescriptions in Colombia. 

3.  Avicanna also hosts a full pipeline of Pharmaceuticals in various stages of trials to address Dermatology, Psychiatry, Neurology, Pain and Oncology. Three of the company’s products are already as far as phase 2.

AND… if that is not enough …

4.  Avicanna’s Colombian cultivation division hosts 500,000 Sq ft of low cost and USDA certified organic Cannabis Cultivation. The company recently Made History As The First Ever Export Of Feminized Hemp Seeds From Colombia To The United States. 7,000,000 Seeds For $380,000, with an additional 75,000,000 Seeds Available For Export In Several Pending Transactions.

Hub On AGORACOM / Corporate Profile

Avicanna $AVCN.ca $AVCNF Announces Pricing of Public Marketed Offering of Units $WEED.ca $TLRY $HARV.ca

Posted by AGORACOM-JC at 12:05 PM on Friday, November 13th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • Company intends to issue the Units at a price of $0.85 per Unit for gross proceeds of a minimum of $5,000,000 and a maximum of $7,000,000 . Each Unit will consist of one common share of the Company and one-half of one common share purchase warrant
  • Each Warrant will be exercisable for one Common Share at a price of $1.20 per share at any time for a period of 36 months following closing of the Offering.

TORONTO , Nov. 13, 2020 – Avicanna Inc. (” Avicanna “, or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce that it has priced its previously announced marketed public offering (the ” Offering “) of units (the ” Units “) of the Company. The Company intends to issue the Units at a price of $0.85 per Unit for gross proceeds of a minimum of $5,000,000 and a maximum of $7,000,000 . Each Unit will consist of one common share of the Company (each a ” Common Share “) and one-half of one common share purchase warrant (each full warrant, a ” Warrant ” and collectively the ” Warrants “). Each Warrant will be exercisable for one Common Share (each a ” Warrant Share “) at a price of $1.20 per share at any time for a period of 36 months following closing of the Offering.

The Offering is being conducted on a “best efforts” basis by a syndicate of agents led by Echelon Wealth Partners Inc., as lead agent and sole-bookrunner, and including Beacon Securities Limited and Canaccord Genuity Corp. (collectively, the ” Agents “).

The Company has granted the Agents an option, exercisable in whole or in part, at the sole discretion of the Agents, at any time for a period of 30 days from and including the closing of the Offering, to purchase from the Company up to an additional 15% of the Units sold under the Offering, on the same terms and conditions of the Offering to cover over-allotments, if any, and for market stabilization purposes (the ” Over-Allotment Option “). The Over-Allotment Option may be exercised by the Agents to purchase additional Units, Common Shares, Warrants or any combination thereof.

The Offering will be completed on a “best efforts” basis through the Agents (i) by way of a short form prospectus to be filed in the Canadian Jurisdictions (ii) on a private placement basis to “accredited investors” meeting ‎one or more ‎of the ‎criteria in Rule 501(a) of ‎Regulation D (” Regulation D “) ‎under the United States Securities Act of 1933 , as amended (the ” U.S. Securities Act “) pursuant to Rule 506(b) ‎of Regulation D and/or ‎Section ‎‎‎4(a)(2) thereof and similar exemptions under ‎applicable state securities ‎‎laws, ‎Qualified Institutional ‎Buyers in the United States pursuant to the registration exemptions provided by Rule 144A of the US ‎Securities Act, and (iii) outside Canada and the United States on a basis which does not require the qualification or registration of any of the Company’s securities under domestic or foreign securities laws.

The Offering is expected to close on or about December 3, 2020 , or such other date as the Company and the Agents may agree. Closing of the Offering is subject to customary closing conditions, including, but not limited to, the execution of an agency agreement and the receipt of all necessary regulatory approvals, including the approval of the securities regulatory authorities and the Toronto Stock Exchange.

The Company intends to use the net proceeds of the Offering for product development, working capital and general corporate purposes.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States . The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Avicanna Inc.

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.

Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:

  • Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
  • RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all 2 developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.

With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.

Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta , Colombia . Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020 , Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia .

Stay Connected

For more information about Avicanna, visit www.avicanna.com , call 1-647-243-5283, or contact Setu Purohit , President by email at [email protected]

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by the Company, including expectations and assumptions regarding the terms, timing and potential completion of the Offering, satisfaction of regulatory requirements in various jurisdictions and the use of proceeds from the Offering.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of manageme nt’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, the delay or failure to receive regulatory approvals, and the risk factors set out in the Company’s annual information form dated April 15, 2020 , filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com .

Avicanna $AVCN.ca $AVCNF Announces Overnight Marketed Public Offering of Units $WEED.ca $TLRY $HARV.ca

Posted by AGORACOM-JC at 4:38 PM on Thursday, November 12th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

  • Announced that it has filed and has been receipted for a preliminary short form prospectus with the securities commissions in Alberta , British Columbia , Manitoba , Ontario and Saskatchewan in connection with a marketed public offering of units of the Company
  • Each Unit will consist of one common share of the Company and one-half of one common share purchase warrant
  • Each Warrant will be exercisable for one Common Share (each a ” Warrant Share “) at any time for a period of 24 months following closing of the Offering
  • Final pricing of the Units, the Warrant exercise price and the determination of the number of Units to be sold pursuant to the Offering will be determined in the context of the market prior to the filing of the final short form prospectus in respect of the Offering

TORONTO , Nov. 12, 2020 – Avicanna Inc. (” Avicanna “, or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce that it has filed and has been receipted for a preliminary short form prospectus with the securities commissions in Alberta , British Columbia , Manitoba , Ontario and Saskatchewan (the ” Canadian Jurisdictions “) in connection with a marketed public offering (the ” Offering “) of units (the ” Units “) of the Company.

Each Unit will consist of one common share of the Company (each a ” Common Share “) and one-half of one common share purchase warrant (each full warrant, a ” Warrant ” and collectively the ” Warrants “). Each Warrant will be exercisable for one Common Share (each a ” Warrant Share “) at any time for a period of 24 months following closing of the Offering. Final pricing of the Units, the Warrant exercise price and the determination of the number of Units to be sold pursuant to the Offering will be determined in the context of the market prior to the filing of the final short form prospectus in respect of the Offering. The Offering will be conducted on a “best efforts” basis by a syndicate of agents led by Echelon Wealth Partners Inc., as lead agent and sole-bookrunner, and including Beacon Securities Limited and Canaccord Genuity Corp. (collectively, the ” Agents “).

The Company has granted the Agents an option, exercisable in whole or in part, at the sole discretion of the Agents, at any time for a period of 30 days from and including the closing of the Offering, to purchase from the Company up to an additional 15% of the Units sold under the Offering, on the same terms and conditions of the Offering to cover over-allotments, if any, and for market stabilization purposes (the ” Over-Allotment Option “). The Over-Allotment Option may be exercised by the Agents to purchase additional Units, Common Shares, Warrants or any combination thereof.

The Offering will be completed (i) by way of a short form prospectus to be filed in the Canadian Jurisdictions (ii) on a private placement basis to “accredited investors” meeting ‎one or more ‎of the ‎criteria in Rule 501(a) of ‎Regulation D (” Regulation D “) ‎under the United States Securities Act of 1933 , as amended (the ” U.S. Securities Act “) pursuant to Rule 506(b) ‎of Regulation D and/or ‎Section ‎‎‎4(a)(2) thereof and similar exemptions under ‎applicable state securities ‎‎laws, ‎Qualified Institutional ‎Buyers in the United States pursuant to the registration exemptions provided by Rule 144A of the US ‎Securities Act, and (iii) outside Canada and the United States on a basis which does not require the qualification or registration of any of the Company’s securities under domestic or foreign securities laws.

The Offering is expected to close on or about December 3, 2020 , or such other date as the Company and the Agents may agree. Closing of the Offering is subject to customary closing conditions, including, but not limited to, the execution of an agency agreement and the receipt of all necessary regulatory approvals, including the approval of the securities regulatory authorities and the Toronto Stock Exchange.

The Company intends to use the net proceeds of the Offering for product development, working capital and general corporate purposes.

The preliminary short form prospectus is available on SEDAR at www.sedar.com .

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States . The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Avicanna Inc.

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.

Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:

  • Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
  • RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all 2 developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.

With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.

Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta , Colombia . Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020 , Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia .

Stay Connected

For more information about Avicanna, visit www.avicanna.com , call 1-647-243-5283, or contact Setu Purohit , President by email at [email protected] .

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by the Company, including expectations and assumptions regarding the terms, timing and potential completion of the Offering, satisfaction of regulatory requirements in various jurisdictions and the use of proceeds from the Offering.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of manageme nt’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, the delay or failure to receive regulatory approvals, and the risk factors set out in the Company’s annual information form dated April 15, 2020 , filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com .

SOURCE Avicanna Inc.